Catalio Capital Management

Australia produces world leading intellectual property in drug development and medical equipment, yet captures virtually none of the downstream commercialisation and job multipliers. This is in part due to underdeveloped domestic preclinical expertise. Proto Axiom on shores this capacity, keeping Australian IP in Australia.

Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with better solutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers. Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease.

Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest and most effective targets.

Xilis is a biotechnology company that develops technologies to guide precision therapy for cancer patients and accelerate drug discovery. The company's platform enables diagnostics, drug screening, and scalable patient-derived models for drug discovery, enabling physicians and pharmaceutical companies to develop tailored treatments for patients by conducting drug screening.

Anagenex is a seed stage biotechnology company building a novel platform for drug discovery focusing on difficult targets.

Sickbay, developed by Medical Informatics Corp., is a software platform designed to enhance patient monitoring and analytics in healthcare settings. It archives, aggregates, and transforms high-resolution waveform data from various medical devices, enabling real-time access and analysis of patient information. The platform supports continuous data collection and employs machine learning and artificial intelligence to deliver predictive analytics that facilitate data-driven medicine and patient-centered care. Sickbay also addresses alarm management by reducing alarm noise and ensuring that relevant alerts reach care providers. This comprehensive approach assists doctors, nurses, hospital administrators, and medical researchers in making informed decisions to improve patient outcomes. Founded in 2010 and headquartered in Houston, Texas, Medical Informatics Corp. aims to provide innovative solutions that enhance the efficiency and effectiveness of healthcare delivery.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Octant Bio is a developer of synthetic technology used to improve health and treat disease. Its technology uses synthetic biology, genome engineering, next-generation sequencing, and computational tools to simultaneously measure the activity of thousands of receptor pathways in human cells that enable scientists to apply machine learning methods to engineer small molecules that interact with multiple receptors and unlock a new potential to treat complex diseases.

Pheast Therapeutics is a cancer immunotherapy company focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. It was founded in 2020 and headquartered in Palo Alto, California.

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients. The company is a group of scientists, technologists, computational biologists, clinicians, and drug hunters who use single-cell genomics and machine learning analysis to find new drugs. Celsius Therapeutics was founded in 2018 and is headquartered in Cambridge, Massachusetts.

PrognomiQ is a technology company that focuses on transforming early disease detection and treatment through multi-omics data. The company generates extensive proteomic, genomic, and metabolomic data to provide insights into complex diseases, aiming to improve patient outcomes. PrognomiQ's innovative approach facilitates the development of advanced test products that enhance the understanding and management of health conditions.

RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency.

Sherlock Biosciences is an engineering biology company offering unparalleled breadth and versatility for diagnostic solutions. It leverages engineering biology tools, including CRISPR and Synthetic Biology, to create molecular diagnostics that can rapidly deliver accurate results for a vast range of needs in virtually any setting. They combine the diagnostic power of SHERLOCK with that of a second core platform technology, Internal Splint-Pairing Expression Cassette Translation Reaction, or INSPECTRTM, to create diagnostic tools that are simple and easy to use in virtually any setting, and at the same time provide accurate, rapid and affordable results. SheSherlock Biosciences was founded in 2019 and is headquartered in Cambridge, Massachusetts, United States.

Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.

Septerna is a biotechnology company that discovers and advances novel small-molecule medicines targeting G protein-coupled receptors. The company's mission is to discover, develop, and commercialize medicines that improve the lives of patients by combining GPCR drug targets with the power of state-of-the-art small molecule drug discovery technologies. Septerna’s Native Complex platform is the engine that will make this happen.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Their revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Hyperfine is the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared point-of-care MRI system. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System™ produces high-quality images at a low magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by an iPad®. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments, operating rooms outside the sterile field, and intensive care units, among others.

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures. The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

Bayesian Health is an adaptive AI platform that offers health systems through clinical AI. The company's adaptive AI is intended to integrate with a hospital's EMR, where it provides actionable early detection flags and key insights displayed on the patient list and/or linked with paging, phone, or other escalation pathways to alert the appropriate clinician. An evidence-based AI/machine learning platform can leverage health systems' significant investment in the EMR as a foundation for patient data and help frontline healthcare providers increase capacity.

Xilis is a biotechnology company that develops technologies to guide precision therapy for cancer patients and accelerate drug discovery. The company's platform enables diagnostics, drug screening, and scalable patient-derived models for drug discovery, enabling physicians and pharmaceutical companies to develop tailored treatments for patients by conducting drug screening.

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from living organisms. By developing a comprehensive database of chemical biodiversity, Enveda aims to accelerate the discovery of new medicines.

Volastra Therapeutics is a biotechnology company developing novel therapies for the treatment of metastatic cancers by exploiting unique insights into chromosomal instability.

Immunai is a biotech company that combines single-cell genomics with ML algorithms to enable high-resolution profiling of the immune system. Immunai's mission is to map the entire immune system and its functions using single-cell genomics and machine learning. Immunai leverages single-cell technologies to profile cells from a blood sample, and uses machine-learning algorithms (powered by its proprietary database) to map the hundreds of cell types and their states to create an immune profile. They work on biomarker discovery and insights that identify how a cell responds to its changing environment. The company is located in New York City, San Francisco, and Tel Aviv, Israel.

Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The Company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of diagnostic devices positioned to drive the future of pathology, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s lightweight platform was purpose-built with pathologists to offer an intuitive user experience, and minimize IT burden and costs while ensuring patient safety and data privacy. Paige’s products deliver insights to pathologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.

Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies. The company developing novel biologics therapies targeting key components of the immune system for the treatment of cancers of unmet need. They are also focused on the discovery, development, and delivery of medicines that alter the treatment landscape and contributing value to patients and society. Sensei Biotherapeutics using its proprietary drug discovery platform to study and understand the tumor microenvironment and identify a new class of cancer immunotherapies that act through new biology and differentiated mechanisms. It brings together scientific leaders in biology, immunology, and oncology along with a highly experienced management team and scientific advisors. The company's platform, ImmunoPhage enables the generation of immune-activating agents that fully engage activation of both the innate and adaptive immune systems. Sensei Biotherapeutics is headquartered in Gaithersburg, Maryland with an office in Boston, MA, USA.

Faze Medicines is a biotechnology company that uses a variety of screening and proteomics techniques to define condensate interaction networks.

Atai Life Sciences is a biotechnology company that develops therapies for mental health disorders. The company focuses on creating treatments using psychedelic compounds and other methods to address conditions such as depression, anxiety, and substance use disorders. Atai collaborates with various partners and research institutions to advance its drug development pipeline, which includes several clinical-stage programs. The product portfolio includes therapies that utilize research in psychedelics and neuroscience. Atai's lead programs feature ketamine-based treatments and other compounds aimed at improving mental well-being. The company works with experts in the field to ensure the efficacy and safety of its therapies. Atai Life Sciences has received recognition for its work in mental health treatment, securing partnerships and funding to support its research initiatives. The company has been acknowledged for its contributions to psychiatry and has gained attention for its efforts to advance the understanding and treatment of mental health disorders.

Glympse Bio develops a powerful new paradigm in diagnostics to enable noninvasive and predictive monitoring of multiple human diseases. The company’s technology uses precisely engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. Glympse Bio’s platform technology was originally developed at MIT, and is founded by a team of world-renowned experts in nanomedicine and biomedical engineering.